TMS therapy and Spravato® in Wesley Chapel and Tampa
Florida TMS Clinic
Call

Off-label for OCD; approved for depression

Spravato® (esketamine) for OCD

Medically reviewed by Khaled Bowarshi, MD, board-certified psychiatristReviewed November 4, 2026

Spravato is not FDA-approved to treat OCD. If OCD and treatment-resistant depression occur together, a psychiatrist may consider Spravato for the depression while evaluating OCD separately. Using it specifically to treat OCD is off-label, and evidence is still preliminary.

Spravato and OCD

When OCD and depression occur together, your evaluation considers both conditions. A depression treatment decision does not replace an OCD-specific plan, which may include exposure and response prevention therapy and medication.

What does the research show?

A 2026 prospective case series followed eight adults with severe treatment-resistant OCD and major depression during 12 weeks of intranasal esketamine treatment. Some patients improved in both symptom groups, but there was no control group and the sample was small. A separate 2013 proof-of-concept randomized crossover study used intravenous racemic ketamine in 15 adults with OCD. That study did not test Spravato nasal spray, so its findings cannot be assumed to establish the nasal product's benefits.

ERP-based cognitive behavioral therapy and established OCD medications remain important parts of evidence-based care. Treatment choices depend on prior adequate trials, tolerability, the role of coexisting depression and individual goals.

Spravato and TMS for OCD

TMS and Spravato have different approved uses, evidence and visit requirements. Certain TMS devices and protocols are cleared for OCD; Spravato is not approved for OCD. There is not enough comparative evidence to prescribe one universal sequence or to promise that combining them improves speed or durability. Your psychiatrist can discuss the evidence relevant to your symptoms, prior treatments and preferences.

Who may be considered

  • Adults with treatment-resistant depression, an approved use of Spravato, who also have OCD
  • OCD is evaluated and treated separately, including ERP-based therapy and medication history
  • Medically appropriate for supervised intranasal therapy and follow-up

What happens during a visit?

Allow time for dosing and at least two hours of monitoring afterward. Monitoring includes breathing and oxygen levels, blood pressure, sedation and dissociation. Your clinician decides when you are ready to leave; some visits take longer.

Arrange a ride home. Do not drive or operate machinery until the next day after a restful sleep.

  • Private, comfortable treatment room
  • Self-administered Spravato® nasal spray under clinician supervision

Risks and safety

Important risks include sedation, dissociation, respiratory depression, increased blood pressure, abuse and misuse. The boxed warning also addresses suicidal thoughts and behaviors. Read the prescribing information and discuss risks with your clinician.

This is a short safety summary, not the complete boxed warning. Read the full prescribing information, including the boxed warning. If you are in immediate crisis, call 988 (Suicide & Crisis Lifeline) or 911.

Esketamine in Wesley Chapel and Tampa

Florida TMS Clinic, Tampa: serving Tampa, South Tampa, Downtown, and Westshore.

Florida TMS Clinic, Wesley Chapel: serving Wesley Chapel, New Tampa, Lutz, Land O' Lakes, and North Tampa communities.

Same-week evaluations are available.

Take the first step

If you have OCD and treatment-resistant depression, our team can evaluate whether Spravato® fits the depression while your OCD care is planned separately.

Frequently asked questions

Medical information on this page is educational and not a substitute for professional advice. Individual results vary.